Stockscreener 앱 받기
924.37
1.39%
-13.07
Lilly Eli Co 주식(LLY)의 최신 뉴스
3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs - Nasdaq
Eli Lilly (LLY) Partners with SanegeneBio for Metabolic Disease Research - GuruFocus
Huge News for Eli Lilly Stock and Novo Nordisk Stock Investors as Companies Make Deal With Trump - The Motley Fool
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here - sharewise.com
Eli Lilly (LLY) Enters $1.2B RNAi Therapeutics Deal with Sanegen - GuruFocus
Eli Lilly inks a licensing deal worth up to $1.2B for RNAi therapeutics - Seeking Alpha
This Unstoppable Growth Stock Just Gave Investors More Reasons to Buy - AOL.com
Eli Lilly's Breakout Is Here—Growing GLP-1 Market Share (NYSE:LLY) - Seeking Alpha
Prediction: Eli Lilly Will Be Worth More Than Berkshire Hathaway by 2030 - MSN
Eli Lilly's (LLY) Mounjaro Tops Sales Charts in India - GuruFocus
SanegeneBio Announces RNAi Licensing and Research Collaboration with Eli Lilly and Company - MarketScreener
Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for Investors. - MSN
Jim Cramer Says “Look, in the End, There’s Eli Lilly and There’s Everybody Else” - MSN
Eli Lilly Rep Says Off-Label Sales Protest Got Her Fired - Law360
Lilly Agreement With Trump Administration Reshapes Patient Access to GLP-1 Obesity Medicines - Pharmaceutical Commerce
Novo Nordisk, Lilly shares slip on US drug pricing deal - The Journal Record
Eli Lilly, Novo down after U.S. drug pricing deal (LLY:NYSE) - Seeking Alpha
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment - Benzinga
Lilly’s Eloralintide Success Sets Bar For Amylin Rivals - Citeline News & Insights
UBS Adjusts Price Target on Eli Lilly to $1,080 From $895, Maintains Buy Rating - MarketScreener
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing DealsWhat Investors Need To Know - Seeking Alpha
Lilly, Novo to lower obesity drug prices in Trump deal - UnionLeader.com
Eli Lilly stock holds Buy rating at TD Cowen despite government pricing deal - Investing.com Canada
Zepbound Maker Eli Lilly Stock Weighs In On Trump Weight-Loss Drug Deal - Investor's Business Daily
Eli Lilly's weight-loss drug Mounjaro is India's top-selling drug in OctoberReuters - Seeking Alpha
Lilly bolsters leadership team with neuroscience and immunology in mind - European Pharmaceutical Review
How Novo Nordisk Gave Up Its Weight-Loss Gains - Bloomberg.com
TD Cowen Reiterates Buy Rating on Eli Lilly (LLY) Post US Government Deal - StreetInsider
Lilly, Novo Nordisk Among Latest Pharma Giants To Commit To Trump's MFN Drug Pricing Policy - Nasdaq
Novo Nordisk, Lilly strike deal with Trump to slash weight-loss drug prices - Reuters
Eli Lilly Appoints Dr. Carole Ho and Promotes Adrienne Brown and Daniel Skovronsky in Leadership Restructure Focused on Neuroscience and Immunology - geneonline.com
Deutsche Bank Adjusts Price Target on Eli Lilly to $1,000 From $955, Maintains Buy Rating - MarketScreener
Eli Lilly's weight-loss therapy Mounjaro tops India drug sales by value in October - Reuters
Lilly announces agreement with US government to lower patient costs - PMLiVE
Eli Lilly and Novo Nordisk Agree to Cut Weight-Loss Drug Prices in U.S. Deal - Yahoo Finance
Eli Lilly's weight loss drug Mounjaro becomes top selling medicine in India by value in October - livemint.com
Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of - simplywall.st
Morgan Stanley Adjusts PT on Eli Lilly and Co. to $1,090 From $1,069, Maintains Overweight Rating - MarketScreener
Citigroup Adjusts Price Target on Eli Lilly and Co. to $1,250 From $1,190, Maintains Buy Rating - MarketScreener
Eli Lilly and Novo Nordisk cut prices of slimming drugs in the US - Il Sole 24 ORE
Eli Lilly’s Weight-Loss Drug Mounjaro Becomes India’s Top-Selling Medicine By Value: Report - Stocktwits
Day 6 of Gains Streak for Eli Lilly Stock with 15% Return (vs. 22% YTD) [11/6/2025] - Trefis
Lilly, Novo to Lower Obesity Drug Prices in Trump Deal - Yahoo Finance
PRESSR: Lilly partners with NVIDIA - TradingView
U.S. pharmaceutical companies Eli Lilly and Novo Nordisk have agreed with the Trump administration t.. - 매일경제
Lilly partners with NVIDIA - ZAWYA
Eli Lilly Partners with US Government to Improve Affordable Access to Obesity Drugs - MarketScreener
Eli Lilly Stock Defies Trump’s GLP-1 Pricing Pressure With 6-Day Rally As Wall Street Cheers FDA Boost And New Weight-Loss Drug Data - Stocktwits
Eli Lilly Shares Surge Following Landmark Pricing Agreement with Trump Administration - AD HOC NEWS
Major Stock Sell-Off by Lilly Endowment Inc Shakes Up Eli Lilly & Co - TipRanks
Lilly, Novo Nordisk Enter Obesity Drug Price Deal With Trump - Law360
Novo, Lilly cut deal with Trump to lower prices of obesity drugs - BioPharma Dive
Eli Lilly CEO talks deal to cut medication prices with the Trump administration - NBC News
Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices - AJMC
Lilly, Novo to discount weight-loss drugs in MFN pricing deal with Trump - FirstWord Pharma
Denali Therapeutics is losing Carole Ho, as she heads to Lilly as head of neuroscienceSan Francisco Business Times - The Business Journals
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth - Investing News Network
Eli Lilly Crushed Novo In Obesity Drug Battle—Trump Now Forces Price Cuts - Benzinga
Eli Lilly expects US FDA approval for oral obesity drug in March 2026 - Reuters
Eli Lilly adds two executives to leadership team amid pipeline push - Investing.com Canada
Denali says chief medical officer Carole Ho to depart to join Eli Lilly - TipRanks
0.21%
0.05%
자본화:
|
볼륨(24시간):